Regulatory approval

Published by the Health Service Executive. Approved

The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab in combination with trastuzumab for reimbursement as a treatment option for the maintenance treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer in adult patients, where this is a continuation of treatment for patients who have completed the chemotherapy component of the treatment.

This is written in the approval document as:

Pertuzumab in combination with trastuzumab for the maintenance treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, where this is a continuation of treatment for patients who have completed the chemotherapy component of the treatment.

Reimbursement

Incomplete Reimbursement

Pertuzumab - ODMS Feb 2014; Trastuzumab - N/A

Citation

Pertuzumab and Trastuzumab Therapy, 2024, version number 3, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6599/726_v3a_Pertuzumab_trastuzumab.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	HER2-positive	Invasive Breast Carcinoma	Pertuzumab, Trastuzumab

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2014-02-01	Health Service Executive	Indication approved for reimbursement.